Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

[11] Wilding G(2001)The QT interval Prog Cardiovasc Dis 43 1-45

[12] Moreno V(2007)Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 3362-3371

[13] Baird RD(2010)QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications Curr Drug Saf 5 54-57

[14] Miranda S(2015)Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the International Federation of Gynecology and Obstetrics (FIGO) Obstet Gynecol 126 171-174

[15] Hylands L(2018)The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer Cancer Chemother Pharmacol 81 497-503

[16] Riisnaes R(2006)Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management AAPS J 8 E89-E94

[17] Forster M(2018)Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients Cancer Chemother Pharmacol 81 39-46

[18] Omlin A(undefined)undefined undefined undefined undefined-undefined

[19] Kreischer N(undefined)undefined undefined undefined undefined-undefined

[20] Thway K(undefined)undefined undefined undefined undefined-undefined

[11] Wilding G(2001)The QT interval Prog Cardiovasc Dis 43 1-45

[12] Moreno V(2007)Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 3362-3371

[13] Baird RD(2010)QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications Curr Drug Saf 5 54-57

[14] Miranda S(2015)Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the International Federation of Gynecology and Obstetrics (FIGO) Obstet Gynecol 126 171-174

[15] Hylands L(2018)The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer Cancer Chemother Pharmacol 81 497-503

[16] Riisnaes R(2006)Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management AAPS J 8 E89-E94

[17] Forster M(2018)Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients Cancer Chemother Pharmacol 81 39-46

[18] Omlin A(undefined)undefined undefined undefined undefined-undefined

[19] Kreischer N(undefined)undefined undefined undefined undefined-undefined

[20] Thway K(undefined)undefined undefined undefined undefined-undefined